<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drug-induced hemolytic anemia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drug-induced hemolytic anemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Drug-induced hemolytic anemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wilma Barcellini, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert A Brodsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 11, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Drugs are not the most common cause of hemolytic anemia. However, when a patient develops hemolysis that may be drug induced, there are several challenges in evaluation and management including determining whether a drug is responsible, which drug is the likely culprit, and whether additional interventions are indicated other than stopping the drug.</p><p>This topic discusses common drugs implicated in causing hemolysis, their mechanisms, patient evaluation, and management. Separate topic reviews discuss the general approach to evaluating hemolytic anemias.</p><p class="bulletIndent1"><span class="glyph">●</span>Children – (See  <a class="medical medical_review" href="/z/d/html/5932.html" rel="external">"Overview of hemolytic anemias in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Adults - (See  <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2853064507"><span class="h1">LISTS OF COMMONLY IMPLICATED DRUGS</span><span class="headingEndMark"> — </span>Drugs that commonly cause hemolytic anemia are listed in the tables; details of their mechanisms are discussed below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune hemolysis</strong> – Immune hemolytic anemia is often caused by antibiotics, especially cephalosporins or penicillins, as well as anti-cancer drugs including platinum compounds and immune checkpoint inhibitors [<a href="#rid1">1-3</a>]. These other implicated drugs are listed in the table  (<a class="graphic graphic_table graphicRef109693" href="/z/d/graphic/109693.html" rel="external">table 1</a>). (See <a class="local">'Immune-mediated'</a> below.)</p><p></p><p class="bulletIndent1">The relative frequency of specific drugs is illustrated in the following case series:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2015 report of 73 patients with drug-induced immune hemolysis identified the following as major causative agents [<a href="#rid4">4</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">Diclofenac</a> – 32 percent</p><p class="bulletIndent3"><span class="glyph">-</span>Piperacillin – 18 percent</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">Ceftriaxone</a> – 16 percent</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">Oxaliplatin</a> – 14 percent</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The Berlin Case-Control Surveillance Study from 2011, which included 134 cases of drug-induced autoimmune hemolytic anemia (AIHA), mostly in an outpatient setting, reported commonly implicated drugs to include beta-lactam antibiotics, cotrimoxazole, <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>, and <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">diclofenac</a> [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two series from the early 2000s reported that cephalosporins were responsible for approximately half of the cases of drug-induced AIHA, followed by penicillins, nonsteroidal antiinflammatory drugs, <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a>/<a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>, and other miscellaneous drugs (<a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">diclofenac</a>, <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">cimetidine</a>, <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a>, and sulfamethoxazole) [<a href="#rid6">6,7</a>]. The 2017 Guidelines from the British Society for Haematology on the management of drug-induced AIHA confirm most of these findings [<a href="#rid8">8</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2022 study reported 82 cases of AIHA associated with immune checkpoint inhibitors, mainly occurring after <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, followed by <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, and <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> [<a href="#rid3">3</a>]. Some cases of AIHA have been reported after chimeric antigen receptor (CAR) T cell infusions. (See  <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Checkpoint inhibitor immunotherapy'</a> and  <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'CAR-T cells'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxidation</strong> – Oxidant injury may be caused by a number of antibiotics and other medicines  (<a class="graphic graphic_table graphicRef74254" href="/z/d/graphic/74254.html" rel="external">table 2</a>). Common examples include <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a>, <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, and <a class="drug drug_general" data-topicid="9761" href="/z/d/drug information/9761.html" rel="external">phenazopyridine</a> [<a href="#rid9">9-18</a>]. (See <a class="local">'Oxidant injury'</a> below.)</p><p></p><p class="bulletIndent1">Oxidant injury may be exacerbated by glucose-6-phosphate dehydrogenase (G6PD) deficiency but can occur in individuals without G6PD deficiency as well. Details are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Avoidance of unsafe drugs and chemicals'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methemoglobinemia</strong> – Methemoglobinemia may be caused by topical anesthetics, certain antibiotics, and nitrites, among others  (<a class="graphic graphic_table graphicRef51406" href="/z/d/graphic/51406.html" rel="external">table 3</a>). (See <a class="local">'Methemoglobinemia'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Topical anesthesia using <a class="drug drug_general" data-topicid="9092" href="/z/d/drug information/9092.html" rel="external">benzocaine</a> spray or cream or <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> (eg, for endoscopy) can cause severe methemoglobinemia with cyanosis and dyspnea [<a href="#rid19">19-24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In some cases, this may be followed by hemolysis, especially after exposure to drugs such as <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> or <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> [<a href="#rid25">25</a>]. The symptoms of methemoglobinemia (dyspnea, cyanosis) can be severe [<a href="#rid19">19-23</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other implicated drugs include nitrites (<a class="drug drug_general" data-topicid="8767" href="/z/d/drug information/8767.html" rel="external">amyl nitrite</a> and butyl nitrite), which may be used to increase sexual arousal; these are primarily inhaled [<a href="#rid26">26-29</a>]. These may be referred to by names such as "locker room," "sweat," "rush," or "poppers."</p><p></p><p class="bulletIndent1">Additional information is presented separately. (See  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'Acquired causes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombotic microangiopathy</strong> – Drugs can cause thrombotic microangiopathy by immune and non-immune mechanisms. Examples are listed in the table  (<a class="graphic graphic_table graphicRef101685" href="/z/d/graphic/101685.html" rel="external">table 4</a>) and discussed separately. (See <a class="local">'Thrombotic microangiopathy'</a> below and  <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Drugs associated with DITMA'</a>.)</p><p></p><p class="headingAnchor" id="H3333556037"><span class="h1">MECHANISMS</span><span class="headingEndMark"> — </span>The two major mechanisms of drug-induced hemolysis are immune destruction of red blood cells (RBCs) and destruction due to oxidant injury, which may be associated with methemoglobinemia. (See <a class="local">'Immune-mediated'</a> below and <a class="local">'Oxidant injury'</a> below.)</p><p class="headingAnchor" id="H526456598"><span class="h2">Immune-mediated</span><span class="headingEndMark"> — </span>Immune destruction of RBCs is generally antibody-mediated. The mechanisms can include several types of antigen-antibody interactions [<a href="#rid5">5-7,30</a>]. In most cases, the antibody-bound (opsonized) RBCs are phagocytosed by reticuloendothelial macrophages in the spleen and/or liver, resulting in extravascular hemolysis. The direct antiglobulin test (DAT; direct Coombs test) is typically positive  (<a class="graphic graphic_figure graphicRef100639" href="/z/d/graphic/100639.html" rel="external">figure 1</a>), although not always so. Occasionally, a metabolite of the drug but not the parent drug itself is responsible, making diagnosis difficult [<a href="#rid6">6</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-dependent</strong> – In drug-dependent reactions, the drug binds to the RBC surface and becomes part of the antigen with which the antibody interacts. These reactions require the drug. The mechanism can be further subdivided based on whether the drug must remain firmly bound to the RBC membrane for antibody binding.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Penicillin type</strong> – In the penicillin type of hapten reaction, the drug remains present on the RBC surface and is required for antibody binding. There are a number of penicillin and cephalosporin antibiotics that can cause hemolysis by this mechanism.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immune complex type</strong> – In the immune complex type (also called innocent bystander, fuadin type, nonpenicillin type, or ternary complex type) of reaction, the drug causes formation of immune complexes that bind to the RBCs and cause complement activation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Passive absorption</strong> – In the passive absorption type, administration of antibody preparations introduces antibodies that can react with the recipient's RBCs. Intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) or <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">Rho(D) immune globulin</a> frequently contain alloantibodies that react with the recipient's RBC antigens (eg, anti-D, anti-A, or anti-B) producing alloimmune hemolysis [<a href="#rid31">31-35</a>]. (See  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects", section on 'Hemolysis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alteration of RBC surface antigen</strong> – In this type of reaction, the drug alters a normal membrane component of the RBC membrane. It can cause immune hemolysis several weeks to months after drug initiation. The DAT (direct Coombs) test is positive, and hemolytic anemia occurs in approximately 10 percent of individuals. This mechanism is less common than the hapten reactions discussed above.</p><p></p><p class="headingAnchor" id="H3669117604"><span class="h2">Oxidant injury</span><span class="headingEndMark"> — </span>All RBCs can be affected by oxidant injury from a variety of drugs. The common denominator among drugs that cause oxidative hemolysis is their interaction with hemoglobin and oxygen, leading to the intracellular formation of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) and other oxidizing radicals. (See <a class="local">'Lists of commonly implicated drugs'</a> above.)</p><p>Two notable underlying disorders can increase susceptibility to oxidant injury, although an underlying disorder does not need to be present:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>G6PD deficiency</strong> – Red blood cells are normally protected from oxidant injury by several enzymatic systems including glutathione and nicotinamide adenine dinucleotide phosphate (NADPH); generation of NADPH requires glucose-6-phosphate dehydrogenase (G6PD)  (<a class="graphic graphic_figure graphicRef77081" href="/z/d/graphic/77081.html" rel="external">figure 2</a>). Individuals with G6PD deficiency have increased susceptibility to oxidant drugs. (See  <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Inciting drugs, chemicals, foods, illnesses'</a>.)</p><p></p><p class="bulletIndent1">Oxidant injury can be especially severe in individuals with G6PD deficiency; however, some drugs can cause oxidant injury in individuals without G6PD deficiency. Thus, a history of G6PD deficiency may be helpful if present, but a negative history cannot be used to eliminate the possibility of oxidative hemolysis. (See <a class="local">'Typical presentation/when to suspect drug-induced hemolysis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemoglobin H disease</strong> – Thalassemic RBCs have increased generation of reactive oxygen species, and elevated levels of antioxidant enzymes in RBCs from individuals with thalassemia suggest ongoing induction of antioxidant mechanisms [<a href="#rid36">36</a>]. Individuals with hemoglobin H disease (alpha thalassemia with loss of three alpha chain genes) may be especially susceptible. </p><p></p><p>Oxidant injury can cause hemolysis via oxygen radical damage to RBC membrane components and cellular proteins. Oxidative injury can also lead to lipid peroxidation, crosslinking of membrane proteins, and the formation of adducts between spectrin and denatured globin [<a href="#rid37">37</a>]. Hemichromes and Heinz bodies (denatured hemoglobin intermediates and precipitated forms, respectively) can interfere with membrane function both directly or via oxidation of membrane proteins and lipids [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/7086.html" rel="external">"Unstable hemoglobin variants", section on 'Hemoglobin precipitation and Heinz body formation'</a>.)</p><p>These erythrocytes also have decreased deformability, a characteristic that promotes trapping in the spleen and in other sinusoidal structures. This trapping can occur regardless of whether Heinz bodies are located against the membrane. Susceptibility to phagocytosis by macrophages may also be increased. This in turn leads to splenic culling of damaged cells by splenic macrophages. (See  <a class="medical medical_review" href="/z/d/html/7134.html" rel="external">"Splenomegaly and other splenic disorders in adults", section on 'Properties of the normal spleen'</a>.)</p><p>In some cases, the oxidative lesions are so severe that there is also intravascular hemolysis, with hemoglobinemia and hemoglobinuria.</p><p>Oxidative stress is associated with the formation of blister cells  (<a class="graphic graphic_picture graphicRef117737" href="/z/d/graphic/117737.html" rel="external">picture 1</a>) and bite cells. Blister cells result from puddling of hemoglobin on one side of the cell and an empty veil of membrane on the other side. Bite cells result from splenic macrophage-mediated removal of this hemoglobin at the edge of the cell. (See <a class="local">'Peripheral blood smear review'</a> below.)</p><p class="headingAnchor" id="H4265390500"><span class="h2">Methemoglobinemia</span><span class="headingEndMark"> — </span>Methemoglobinemia is not always associated with hemolysis but may cause hemolysis in some cases, and treatment of methemoglobinemia with <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">methylene blue</a> can cause hemolysis by increasing oxidative stress in individuals with G6PD deficiency. Ascorbic acid (<a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">vitamin C</a>) is recommended to treat methemoglobinemia in G6PD-deficient patients. (See  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'Ascorbic acid (vitamin C)'</a>.)</p><p>Methemoglobin results from oxidation of the iron in heme (removal of an electron, with conversion from the reduced form [ferrous iron; Fe<sup>2+</sup>] to the oxidized form [ferric iron; Fe<sup>3+</sup>]) [<a href="#rid39">39</a>]. In normal physiology, this process can be coupled with one of several other redox reactions such as the reduction of nicotinamide-adenine dinucleotide (NAD) to NADH or the reduction of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) to water (H<sub>2</sub>O). (See  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'What is methemoglobin?'</a>.)</p><p>Methemoglobin levels are usually kept low (typically &lt;1 to 3 percent) by the enzymes cytochrome b5 reductase (also called diaphorase or methemoglobin reductase) and NADPH-(flavin) methemoglobin reductase or by nonenzymatic processes [<a href="#rid37">37,38</a>]. However, these processes can become overwhelmed in the setting of significant oxidant stress induced by drugs. (See  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'How are the levels regulated?'</a>.)</p><p>The 2021 Recommendations for diagnosis and treatment of methemoglobinemia provide an overview of acquired forms (the most common, mainly due to oxidating substances) and inherited forms, which are due either to autosomal recessive variants in the cytochrome b5 reductase gene or to autosomal dominant variants in the globin genes, collectively known as Hb M disease [<a href="#rid40">40</a>]. Commonly implicated drugs include topical anesthetics such as <a class="drug drug_general" data-topicid="9092" href="/z/d/drug information/9092.html" rel="external">benzocaine</a> or <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> (sprays or creams used for endoscopy or transesophageal echocardiography, even at small doses), <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a>, <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, and nitrites (<a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> or nitric oxide) [<a href="#rid39">39,41</a>]. (See  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'Causes of methemoglobinemia'</a>.)</p><p>Some of these drugs cause methemoglobin formation via direct oxidation of the heme in hemoglobin; others produce oxygen free radicals that oxidize the heme [<a href="#rid25">25</a>].</p><p>There are two major adverse consequences:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decreased tissue oxygenation</strong> – The ferric hemes in methemoglobin cannot bind oxygen, and the ferrous hemes complexed with them have a left-shifted hemoglobin-oxygen dissociation curve  (<a class="graphic graphic_figure graphicRef81216" href="/z/d/graphic/81216.html" rel="external">figure 3</a>) [<a href="#rid42">42</a>]. Patients can become severely cyanotic due to decreased oxygen delivery to the tissues.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemolysis</strong> – Methemoglobin is not directly harmful to red cells. However, if there is a large oxidative assault, methemoglobin is converted to hemichromes (variably denatured hemoglobin intermediates). Continued oxidation results in irreversible hemichrome oxidation, precipitation, and eventually the formation of Heinz bodies. Removal of membrane-attached Heinz bodies via the monocyte-macrophage system in the spleen can produce bite cells  (<a class="graphic graphic_picture graphicRef117737" href="/z/d/graphic/117737.html" rel="external">picture 1</a>) [<a href="#rid43">43,44</a>].</p><p></p><p>Intravenous <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">methylene blue</a> is the primary treatment for symptomatic methemoglobinemia; methylene blue is converted to leukomethylene blue, which then reduces the heme group from methemoglobin to hemoglobin via the NADPH-dependent hexose monophosphate shunt pathway. (See <a class="local">'Therapy for methemoglobinemia'</a> below.)</p><p>The reduction of methemoglobin by <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">methylene blue</a> depends on NADPH generated by G6PD. In individuals with G6PD deficiency, methylene blue may be ineffective and is potentially dangerous since it has oxidant potential that may worsen hemolysis [<a href="#rid45">45-47</a>]. (See <a class="local">'Considerations in individuals with G6PD deficiency'</a> below.)</p><p class="headingAnchor" id="H2253464429"><span class="h2">Thrombotic microangiopathy</span><span class="headingEndMark"> — </span>The mechanisms of drug-induced thrombotic microangiopathy (DITMA), which can include immune-mediated and non-immune processes  (<a class="graphic graphic_table graphicRef101685" href="/z/d/graphic/101685.html" rel="external">table 4</a>), are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Pathophysiology'</a>.)</p><p class="headingAnchor" id="H463547174"><span class="h2">Purine analogs</span><span class="headingEndMark"> — </span>Purine analogs (<a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9756" href="/z/d/drug information/9756.html" rel="external">pentostatin</a>, and <a class="drug drug_general" data-topicid="9272" href="/z/d/drug information/9272.html" rel="external">cladribine</a>) are all associated with a higher risk of autoimmune hemolytic anemia when administered in the setting of lymphoproliferative disorders. The data are most compelling with fludarabine, especially in the setting of chronic lymphocytic leukemia (CLL). Most, but not all cases, are associated with a positive direct antiglobulin test [<a href="#rid48">48,49</a>]. (See  <a class="medical medical_review" href="/z/d/html/4504.html" rel="external">"Overview of the complications of chronic lymphocytic leukemia", section on 'Autoimmune hemolytic anemia'</a>.)</p><p>Management includes discontinuation of the purine analog and treatment with a glucocorticoid, similar to other drug-induced immune hemolysis. (See <a class="local">'Drug discontinuation'</a> below and <a class="local">'Therapies for AIHA'</a> below.)</p><p class="headingAnchor" id="H3950841"><span class="h2">Other mechanisms</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">Ribavirin</a> is an orally active nucleoside analog antiviral agent used to treat hepatitis C virus (HCV) infection. It has been associated with a dose-dependent hemolytic anemia associated with a reduction in erythrocyte ATP. Polymorphisms of the enzyme inosine triphosphatase (ITPA) may be involved in this process. Hemolysis resolves upon discontinuation and stabilizes with dose reduction. This subject is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Ribavirin'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="17088" href="/z/d/drug information/17088.html" rel="external">Artesunate</a>, an artemisinin derivative, is a potent antimalarial agent. The drug kills malarial parasites, following which splenic "pitting" (removal of dead parasites from the RBCs) occurs, with reduced RBC survival in the circulation [<a href="#rid50">50-52</a>]. Clinically, this phenomenon has been associated with a brief, self-limited episode of hemolytic anemia occurring more than one week after treatment of severe malaria with parenteral artesunate (after symptoms of malaria have resolved) [<a href="#rid53">53,54</a>]. (See  <a class="medical medical_review" href="/z/d/html/5667.html" rel="external">"Treatment of severe malaria"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute and occasionally severe hemolytic anemia is a rare complication of therapy with interferon alfa [<a href="#rid55">55-60</a>]. Most patients have an immune mechanism of hemolysis, but the Coombs test may be negative [<a href="#rid60">60,61</a>]. (See <a class="local">'Immune-mediated'</a> above.)</p><p></p><p class="headingAnchor" id="H922143562"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The first step in evaluating suspected drug-induced hemolytic anemia is to recognize the signs and symptoms of hemolysis. (See  <a class="medical medical_review" href="/z/d/html/5932.html" rel="external">"Overview of hemolytic anemias in children"</a> and  <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults", section on 'Laboratory confirmation of hemolysis'</a>.)</p><p>Symptoms should be reviewed and a history of exposures obtained, with a focus on new medications as well as other possible drug or chemical exposures when the hemolysis began (and the timing relative to the initiation of new medicines). Causative drugs are listed above. (See <a class="local">'Lists of commonly implicated drugs'</a> above.) </p><p>When drug-induced hemolytic anemia is suspected, inspection of the peripheral blood smear can help determine the suspected type of hemolysis, which can have major implications for further testing and for management. (See <a class="local">'Peripheral blood smear review'</a> below.)</p><p>More specialized testing is based on the implicated drug(s) and on other clinical manifestations. (See <a class="local">'Laboratory testing based on initial findings'</a> below.)</p><p class="headingAnchor" id="H1016204726"><span class="h2">Typical presentation/when to suspect drug-induced hemolysis</span><span class="headingEndMark"> — </span>Drug-induced hemolytic anemia is often acute and severe, and it may occur at various intervals following introduction of the drug. In a series of children who developed hemolytic anemia with <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, symptom onset was sudden and often within one hour of receiving the drug, with intravascular hemolysis and hemoglobin levels decreasing to &lt;5 g/dL [<a href="#rid62">62</a>]. Many of these children had received ceftriaxone on previous occasions without obvious reactions.</p><p>When hemolysis is severe, patients may experience sudden onset of pallor, fatigue, jaundice, dark urine, abdominal pain, or back pain. Typical symptoms of hemolytic anemia include those associated with anemia (fatigue, weakness, dyspnea, symptoms related to volume depletion) as well as hemolysis (jaundice; in some cases dark or red urine due to hemoglobinuria). These are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults", section on 'History and physical examination'</a>.)</p><p>In others, hemolysis begins within days to weeks of exposure to a new drug. Oxidative stress is usually the most acute, followed by drug-induced autoimmune hemolytic anemia (AIHA). Drug-induced thrombotic microangiopathies (DITMA) may have an acute or subacute onset and may start weeks or even months after exposure to the putative agent.</p><p>Certain types of drug-induced hemolysis have other characteristic features that may increase the clinical suspicion:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxidative hemolysis</strong> – Glucose-6-phosphate dehydrogenase (G6PD) deficiency is more common in persons with African, Asian, or Mediterranean ancestry; however, it can be observed in any ethnic background and many drugs can cause oxidative hemolysis in individuals who do not have G6PD deficiency  (<a class="graphic graphic_table graphicRef74254" href="/z/d/graphic/74254.html" rel="external">table 2</a>). Any history of prior similar episodes with oxidant drug or food exposure that would suggest G6PD deficiency is also relevant. (See  <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmune hemolysis</strong> – There may be a history of exposure to a drug known to cause AIHA  (<a class="graphic graphic_table graphicRef109693" href="/z/d/graphic/109693.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombotic microangiopathy</strong> – There may be a history of exposure to <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a>  (<a class="graphic graphic_table graphicRef60296" href="/z/d/graphic/60296.html" rel="external">table 5</a>) or a drug associated with DITMA  (<a class="graphic graphic_table graphicRef101685" href="/z/d/graphic/101685.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methemoglobinemia</strong> – Classic symptoms of methemoglobinemia include cyanosis with a normal arterial oxygen tension (PaO<sub>2</sub>) and a dark brown (chocolate color, dark red, or brownish blue) appearance of the blood that does not resolve upon oxygenation. Methemoglobin levels less than 15 percent are usually asymptomatic; levels of 50 percent or more are life-threatening. Methemoglobinemia and associated hemolysis may be more pronounced in individuals with G6PD deficiency [<a href="#rid29">29</a>]. Inherited forms, both the autosomal recessive variants of the cytochrome b5 reductase or the autosomal dominant Hb M diseases, are more susceptible to oxidants. The diagnosis requires specialized enzyme activity and genetic testing. (See  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia"</a>.)</p><p></p><p class="headingAnchor" id="H1240294689"><span class="h2">Peripheral blood smear review</span><span class="headingEndMark"> — </span>Suspected drug-induced hemolytic anemia is evaluated by reviewing the blood smear, which can be used to determine the likely cause(s) and appropriate laboratory testing. Attention should be paid to the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Bite cells, blister cells, or irregularly shaped red blood cells (poikilocytosis) suggest oxidative hemolysis  (<a class="graphic graphic_picture graphicRef117737" href="/z/d/graphic/117737.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spherocytes or microspherocytes suggest immune hemolysis  (<a class="graphic graphic_picture graphicRef70611" href="/z/d/graphic/70611.html" rel="external">picture 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Schistocytes suggest a thrombotic microangiopathy (TMA) or other cause of microangiopathic hemolytic anemia such as disseminated intravascular coagulation (DIC)  (<a class="graphic graphic_picture graphicRef70851" href="/z/d/graphic/70851.html" rel="external">picture 3</a>).</p><p></p><p>Additional findings that may be present on the blood smear are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">"Evaluation of the peripheral blood smear"</a>.)</p><p class="headingAnchor" id="H1729265295"><span class="h2">Laboratory testing based on initial findings</span></p><p class="headingAnchor" id="H1893453525"><span class="h3">Commonly used tests</span><span class="headingEndMark"> — </span>Patients being evaluated for drug-induced hemolysis or drug-induced hemolytic anemia are presumed to already have documented hemolytic anemia, with one or more of the typical findings such as low haptoglobin, elevated reticulocyte count, and high lactate dehydrogenase (LDH) or indirect bilirubin, as listed in the table  (<a class="graphic graphic_table graphicRef126234" href="/z/d/graphic/126234.html" rel="external">table 6</a>). Haptoglobin is an acute phase reactant; thus, it may be normal in patients with concomitant infection or inflammation [<a href="#rid63">63</a>]. The general approach to evaluating and confirming hemolytic anemia is presented separately. (See  <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults", section on 'Diagnostic approach'</a>.)</p><p>The following tests are often appropriate for suspected drug-induced hemolysis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>DAT (Coombs test)</strong> – The direct antiglobulin test (DAT) is one of the first tests done when the cause of hemolysis is unclear. If a drug is suspected and the mechanism is not obvious, DAT (Coombs) testing is appropriate. (See  <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults", section on 'Cause not obvious - start with Coombs test'</a>.)</p><p></p><p class="bulletIndent1">Reports have described positive DAT for immunoglobulin (Ig) G and complement (C3, related to <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>), as well as IgM antibodies in serum [<a href="#rid62">62</a>]. Penicillin reactions may be negative for C3 [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1">A positive DAT (Coombs test) is consistent with immune hemolysis. It does not distinguish between drug-induced autoimmune hemolysis, autoimmune hemolysis unrelated to a drug, or alloimmune hemolysis (associated with transfusion or other exposure to allogeneic blood). However, a positive DAT does not eliminate the possibility of a non-immune mechanism since some individuals have a positive DAT that is not clinically significant. Likewise, a negative DAT does not always eliminate the possibility of an immune mechanism. (See <a class="local">'Purine analogs'</a> above.)</p><p></p><p class="bulletIndent1">Hapten and drug-independent antibodies (eg, <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">methyldopa</a>) most often have a DAT positive for IgG, while the immune complex type is typically only positive for complement. A type and screen should also always be performed. The immune complex type and hapten type do not generally have any reactivity in the standard indirect antiglobulin test. A panagglutinin suggests a drug-independent type of antibody. To distinguish, an eluate can be performed, which should be positive with drug-independent and negative if hapten or immune complex type. The type and screen will also be useful if the patient needs a transfusion (and the serology may be complex for ruling out underlying alloantibodies, especially drug-independent types).</p><p></p><p class="bulletIndent1">Additional details of the evaluation are presented separately. (See  <a class="medical medical_review" href="/z/d/html/5932.html" rel="external">"Overview of hemolytic anemias in children", section on 'Diagnostic approach'</a> and  <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>G6PD testing</strong> – Testing for G6PD deficiency is appropriate if oxidative hemolysis is suspected. Typically this involves using an assay of G6PD activity. This testing may be negative in the setting of severe hemolysis (because all of the G6PD-deficient cells have been destroyed), and repeat testing following recovery may be warranted. (See  <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Diagnostic evaluation'</a>.)</p><p></p><p class="headingAnchor" id="H1248307161"><span class="h3">Additional tests for selected individuals</span><span class="headingEndMark"> — </span>Additional testing may be appropriate for certain drugs and certain clinical manifestations.</p><p class="headingAnchor" id="H3451103996"><span class="h4">Testing for intravascular hemolysis</span><span class="headingEndMark"> — </span>Hemolysis can occur extravascularly (in the spleen and/or liver) or intravascularly (in the circulation). Extravascular hemolysis is typical of drug-induced AIHA and oxidant injury, but in severe cases, there may be a component of intravascular and extravascular hemolysis.</p><p>Intravascular hemolysis due to a drug can occur in drug-induced thrombotic microangiopathy (DITMA) (see <a class="local">'Thrombotic microangiopathy'</a> above). This can cause serious complications including acute kidney injury and disseminated intravascular coagulation due to the release of free hemoglobin or heme into the circulation. (See  <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults", section on 'Site of RBC destruction'</a>.)</p><p>Intravascular hemolysis may be suspected in an individual with abdominal or back pain, dark (or red) urine, or dark (or red) serum or plasma. If suspected, testing should be performed with the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum or plasma for free hemoglobin</p><p class="bulletIndent1"><span class="glyph">●</span>Coagulation testing (prothrombin time [PT], activated partial thromboplastin time [aPTT], and fibrinogen)</p><p class="bulletIndent1"><span class="glyph">●</span>Review of the blood smear for other causes of intravascular hemolysis (eg, schistocytes, suggestive of disseminated intravascular coagulation [DIC] or a TMA). (See <a class="local">'Testing for a TMA'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Flow cytometry to evaluate for possible paroxysmal nocturnal hemoglobinuria (PNH; may be omitted if there are obvious schistocytes on the blood smear) </p><p></p><p class="headingAnchor" id="H1823995869"><span class="h4">Testing for a TMA</span><span class="headingEndMark"> — </span>Thrombotic microangiopathies (TMAs) can be drug-induced or due to another condition such as thrombotic thrombocytopenic purpura (TTP; due to severe ADAMTS13 deficiency) or a defect in complement regulation.</p><p>It is often appropriate to test for TTP in patients with suspected TMA because TTP is potentially life-threatening and therapeutic plasma exchange can be life-saving. The approach to suspected TMA and typical findings related to DITMA are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a> and  <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a>.)</p><p class="headingAnchor" id="H463312273"><span class="h4">Drug-dependent antibody testing</span><span class="headingEndMark"> — </span>Drug-dependent antibody testing can be used to evaluate suspected drug-induced autoimmune hemolytic anemia (AIHA), such as with drugs known to cause AIHA  (<a class="graphic graphic_table graphicRef109693" href="/z/d/graphic/109693.html" rel="external">table 1</a>) or microspherocytes on the blood smear.</p><p>However, there are several caveats with the use of this testing that make it unsuitable for immediate management decisions:</p><p class="bulletIndent1"><span class="glyph">●</span>It is often impossible to reliably distinguish between the blood smear findings of warm AIHA from drug-induced AIHA because microspherocytes will be present in both cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testing for drug-dependent antibodies can only be performed in specialized laboratories, and the turnaround time is approximately one week.</p><p></p><p>Thus, detection of drug-dependent antibodies does not appreciably alter immediate management, as long as the responsible drug has been stopped.</p><p>Detection of drug-dependent antibodies can be useful to avoid future drug-induced hemolytic anemia, and this testing can be especially helpful in patients with acute-onset, unexplained hemolytic anemia temporally associated with the addition of a medication or drug that is associated with drug-induced hemolytic anemia (eg, a penicillin or a cephalosporin).</p><p class="headingAnchor" id="H660892062"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H3893137666"><span class="h2">Overview of management</span><span class="headingEndMark"> — </span>The intensity of intervention depends on the severity of hemolysis, which can range from mild, asymptomatic or unrecognized hemolysis without anemia to fatal hemolytic reactions [<a href="#rid2">2,62</a>]. The severity of hemolysis is typically apparent from the degree of anemia, lactate dehydrogenase (LDH) and bilirubin elevations, and presence of free heme in the serum and urine. (See <a class="local">'Commonly used tests'</a> above and <a class="local">'Testing for intravascular hemolysis'</a> above.)</p><p>Discontinuation of the presumed offending drug is the cornerstone of treatment. (See <a class="local">'Drug discontinuation'</a> below.)</p><p>In severe disease, aggressive therapy must be directed toward the anemia (eg, transfusion). Transfusion may be helpful in patients who are in shock [<a href="#rid65">65</a>]. If present, other hematologic complications of the drug such as thrombocytopenia may also require treatment. (See <a class="local">'Indications for transfusions'</a> below and  <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a>.) </p><p>Individuals with intravascular hemolysis who develop acute kidney injury (AKI), kidney failure, and/or disseminated intravascular coagulation (DIC) may require aggressive hydration, dialysis, and other supportive care. (See  <a class="medical medical_review" href="/z/d/html/14036.html" rel="external">"Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)"</a> and  <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a>.)</p><p>For some individuals with hemolytic anemia of unclear mechanism in which the role of a medication(s) is unclear, it may be prudent to give presumptive treatment for the other possible causes until the results of definitive testing are available. Hematology and transfusion medicine input may be sought in these decisions. (See <a class="local">'Therapies for AIHA'</a> below.)</p><p>Autoimmune hemolytic anemia (AIHA) cases following immune checkpoint inhibitors, which are often severe, require discontinuation of the drug, transfusions, administration of steroids, intravenous immune globulins, plasma-exchange, and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in some relapsed/refractory patients. One of the main discussed issues is the rechallenge with immune checkpoint inhibitor after complete resolution of AIHA, as experience is very limited. </p><p>For those with methemoglobinemia, therapy such as <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">methylene blue</a> may be appropriate, as long as the individual does not have glucose-6-phosphate dehydrogenase (G6PD) deficiency. Treatment of methemoglobinemia in the setting of G6PD deficiency is usually done with ascorbic acid. (See <a class="local">'Therapy for methemoglobinemia'</a> below and <a class="local">'Considerations in individuals with G6PD deficiency'</a> below.)</p><p class="headingAnchor" id="H3240581682"><span class="h2">Drug discontinuation</span><span class="headingEndMark"> — </span>The principle treatment for drug-induced hemolytic anemia is removing the exposure by discontinuing the implicated drug(s). This is done in virtually all patients with hemolytic anemia and a high likelihood of a drug-induced mechanism. </p><p>In most cases, eliminating exposure to the implicated drug is sufficient for management. Hemolysis will abate, and the hemoglobin level will rise over the next few days to weeks, with no further interventions needed. The rate of recovery depends on the rate of clearance of the drug (or a drug metabolite responsible for hemolysis).</p><p>The implicated drug should be clearly noted in the patient's medical record and is generally avoided indefinitely. It is appropriate to list the medication in the drug allergy section of the medical record. In some cases such as oxidant hemolysis leading to a new diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency, other drugs in the same class should also be avoided. (See <a class="local">'Considerations in individuals with G6PD deficiency'</a> below.)</p><p>Generally, individuals with chronic lymphocytic leukemia (CLL) who develop immune hemolysis related to a purine analog (such as <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a>) should avoid the drug, especially since many other options are available. There may be individuals for whom fludarabine can be restarted as part of a combination regimen, although this is rare since fludarabine is seldom used for CLL. (See  <a class="medical medical_review" href="/z/d/html/4545.html" rel="external">"Overview of the treatment of chronic lymphocytic leukemia"</a>.)</p><p class="headingAnchor" id="H2291626191"><span class="h2">Indications for transfusions</span><span class="headingEndMark"> — </span>Red blood cell transfusions are given for severe, symptomatic anemia or anemia that is rapidly progressing and expected to become severe without transfusion.</p><p>Typically a threshold of 7 g/dL is used, but this does not replace the judgment of the treating clinician(s) in deciding whether a higher or lower threshold is suitable for the patient based on their age (young people can often tolerate a lower hemoglobin level), medical history, and severity of symptoms. (See  <a class="medical medical_review" href="/z/d/html/5910.html" rel="external">"Red blood cell transfusion in infants and children: Indications"</a> and  <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults"</a>.)</p><p>If possible, blood for certain testing may be obtained prior to starting the transfusions, but if needed, transfusions should <strong>not </strong>be withheld while obtaining or awaiting the results of laboratory testing. (See <a class="local">'Laboratory testing based on initial findings'</a> above.)</p><p>It may be challenging to find crossmatch-compatible blood in an individual with a positive indirect antiglobulin test (IAT; indirect Coombs test) (see <a class="local">'Commonly used tests'</a> above), as this may mask underlying alloantibodies. However, blood should <strong>not </strong>be withheld due to crossmatch incompatibility for individuals with serious or life-threatening anemia. The transfusion medicine service or blood bank can assist in weighing the risks and benefits of transfusion in this setting. Transfusion may be lifesaving in individuals with severe anemia. (See  <a class="medical medical_review" href="/z/d/html/7954.html" rel="external">"Red blood cell (RBC) transfusion in individuals with serologic complexity", section on 'Communication'</a>.)</p><p class="headingAnchor" id="H989297064"><span class="h2">Therapies for AIHA</span><span class="headingEndMark"> — </span>The primary therapy for drug-induced AIHA is drug discontinuation. </p><p>Symptomatic autoimmune hemolytic anemia (AIHA), including drug-induced AIHA, can be treated with immunomodulatory therapies including glucocorticoids and/or intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG). Often these therapies are used when it is not immediately clear whether the cause is drug induced or autoimmune without a drug and/or when the anemia is severe and there is insufficient time to observe for a response to drug discontinuation. Typical dosing is equivalent to <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 1 to 2 mg/kg daily. Details of dosing and supporting evidence are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7078.html" rel="external">"Warm autoimmune hemolytic anemia (AIHA) in adults", section on 'Glucocorticoids with or without rituximab as first-line agents'</a>.)</p><p>Glucocorticoids and <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> may be omitted in asymptomatic individuals. </p><p>In a series from 2019, glucocorticoids were effective for most cases of AIHA associated with immune checkpoint inhibitors [<a href="#rid2">2</a>]. Severe and relapsing cases of AIHA following immune checkpoint inhibitor therapy may require further therapies including <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>, therapeutic plasma exchange, and/or <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>. </p><p class="headingAnchor" id="H1416589950"><span class="h2">Therapy for methemoglobinemia</span><span class="headingEndMark"> — </span>Hemolysis is often a consequence of drug-induced methemoglobinemia  (<a class="graphic graphic_table graphicRef51406" href="/z/d/graphic/51406.html" rel="external">table 3</a>). Symptoms typically occur with methemoglobin levels greater than 15 to 20 percent; levels of 50 percent or more are life-threatening  (<a class="graphic graphic_table graphicRef99739" href="/z/d/graphic/99739.html" rel="external">table 7</a>). (See <a class="local">'Methemoglobinemia'</a> above.)</p><p>Treatment to reduce the level of methemoglobin is indicated in symptomatic patients. This is discussed in detail separately and summarized briefly below. (See  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'Management (acquired/toxic)'</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">Methylene blue</a> – First-line therapy for symptomatic methemoglobinemia typically involves administration of methylene blue (MB; given intravenously at a dose of 1 to 2 mg/kg over 5 minutes [in a 1 g/dL solution]). MB provides an artificial electron acceptor for the reduction of methemoglobin to hemoglobin. It has a rapid and dramatic action and is the treatment of choice in the majority of patients who require treatment. However, MB should be avoided in individuals with G6PD deficiency, and caution should be used to avoid overdosage. Since co-oximetry detects MB as methemoglobin, this technique cannot be used to follow the response of methemoglobin levels to treatment with MB. Dosing and details of MB administration are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'Methylene blue (MB)'</a>.)</p><p></p><p class="bulletIndent1">Lack of a rapid response to <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">methylene blue</a> (failure of the blood to turn from chocolate color to normal red color; failure of the methemoglobin level to decrease) is highly suggestive of concomitant G6PD deficiency. (See <a class="local">'Mechanisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care including dextrose</strong> – Supportive care may include hydration, oxygenation, or mechanical ventilation. Dextrose should be given, as it provides a source of nicotinamide adenine dinucleotide (NADH) via glycolysis [<a href="#rid25">25</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ascorbic acid</strong> – Ascorbic acid (<a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">vitamin C</a>) is an alternative treatment for symptomatic methemoglobinemia; this is the treatment of choice in individuals with G6PD deficiency. In the acute setting, it should be administered intravenously with doses up to 10 grams daily. (See <a class="local">'Considerations in individuals with G6PD deficiency'</a> below.)</p><p></p><p class="bulletIndent1">Oral <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">vitamin C</a> at a dose of 300 to 600 mg daily can be used as an adjuvant to <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">methylene blue</a> in patients without G6PD deficiency. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemoperfusion</strong> – In certain poisonings such as with paraquat (inadvertent or by attempted suicide), profound methemoglobinemia can develop rapidly (to levels of 20 to 100 percent within hours) and may be followed by Heinz body hemolytic anemia [<a href="#rid66">66,67</a>]. Treatment may include hemoperfusion. (See  <a class="medical medical_review" href="/z/d/html/325.html" rel="external">"Enhanced elimination of poisons", section on 'Extracorporeal removal'</a>.)</p><p></p><p class="headingAnchor" id="H918214658"><span class="h2">Considerations in individuals with G6PD deficiency</span><span class="headingEndMark"> — </span>Individuals with suspected or documented G6PD deficiency generally can be treated with drug discontinuation. However, additional considerations may apply in some cases: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe anemia</strong> – Transfusions may be indicated for severe anemia and aggressive hydration may be prudent if there is a major component of intravascular hemolysis. (See <a class="local">'Indications for transfusions'</a> above and  <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Treatment of acute hemolytic episodes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methemoglobinemia</strong> – Individuals with G6PD deficiency who also have methemoglobinemia should not be treated with <a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">methylene blue</a>, because methylene blue can cause oxidative hemolysis in these individuals and potentially worsen anemia. Further, methylene blue is unlikely to help in the setting of G6PD deficiency because its mechanism of action requires generation of nicotinamide adenine dinucleotide phosphate (NADPH), which is impaired in G6PD-deficient individuals.(See <a class="local">'Oxidant injury'</a> above.)</p><p></p><p class="bulletIndent1">Options for treating methemoglobinemia in individuals with G6PD deficiency who have symptomatic methemoglobinemia include ascorbic acid (<a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">vitamin C</a>) and exchange transfusions. Vitamin C is given intravenously at doses up to 10 grams daily [<a href="#rid68">68,69</a>]. Exchange transfusions have been used with reported success in severe cases [<a href="#rid45">45,46,70</a>]. (See  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'Management (acquired/toxic)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of other unsafe drugs</strong> – Members of the care team should be made aware of the diagnosis of G6PD deficiency, and the importance of avoiding other unsafe drugs and unsafe foods should be emphasized. (See  <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Avoidance of unsafe drugs and chemicals'</a> and  <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Dietary restrictions'</a>.)</p><p></p><p class="headingAnchor" id="H3653001635"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111043.html" rel="external">"Society guideline links: Anemia in adults"</a>.)</p><p class="headingAnchor" id="H368893974"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/86967.html" rel="external">"Patient education: Glucose-6-phosphate dehydrogenase deficiency (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/83062.html" rel="external">"Patient education: Autoimmune hemolytic anemia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H5798500"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lists of drugs</strong> – Drugs can cause hemolysis by various mechanisms. The tables list commonly implicated drugs based on mechanism:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immune (antibody-mediated), which can be drug-dependent or drug-independent  (<a class="graphic graphic_table graphicRef109693" href="/z/d/graphic/109693.html" rel="external">table 1</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Oxidation  (<a class="graphic graphic_table graphicRef74254" href="/z/d/graphic/74254.html" rel="external">table 2</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Methemoglobinemia  (<a class="graphic graphic_table graphicRef51406" href="/z/d/graphic/51406.html" rel="external">table 3</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Thrombotic microangiopathy (TMA)  (<a class="graphic graphic_table graphicRef101685" href="/z/d/graphic/101685.html" rel="external">table 4</a>)</p><p></p><p class="bulletIndent1">Details are discussed above. (See <a class="local">'Lists of commonly implicated drugs'</a> above and <a class="local">'Mechanisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> – The first step is recognizing signs and symptoms of hemolysis. The exposure history focuses on new medications and other drug or chemical exposures. (See <a class="local">'Typical presentation/when to suspect drug-induced hemolysis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood smear</strong> – The peripheral blood smear helps determine the suspected type of hemolysis. Bite and blister cells suggest oxidative hemolysis  (<a class="graphic graphic_picture graphicRef117737" href="/z/d/graphic/117737.html" rel="external">picture 1</a>), which can occur in individuals with or without glucose-6-phosphate dehydrogenase (G6PD) deficiency; spherocytes suggest immune hemolysis  (<a class="graphic graphic_picture graphicRef70611" href="/z/d/graphic/70611.html" rel="external">picture 2</a>); and schistocytes suggest a TMA  (<a class="graphic graphic_picture graphicRef70851" href="/z/d/graphic/70851.html" rel="external">picture 3</a>). Some causes of drug-induced hemolysis are medical emergencies; if a blood smear is not available it should be requested and reviewed as promptly as possible. (See <a class="local">'Peripheral blood smear review'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory testing</strong> – Testing is guided by the clinical presentation and suspected culprit drug(s). Typical findings associated with hemolysis include decreased haptoglobin, increased lactate dehydrogenase (LDH), and increased indirect bilirubin, as summarized in the table  (<a class="graphic graphic_table graphicRef126234" href="/z/d/graphic/126234.html" rel="external">table 6</a>). (See <a class="local">'Laboratory testing based on initial findings'</a> above.)</p><p></p><p class="bulletIndent1">Immune hemolysis causes a positive direct antiglobulin (Coombs) test (DAT). Intravascular hemolysis produces free heme in blood or urine. Individuals with thrombotic thrombocytopenia (schistocytes on the blood smear) have ADAMTS13 deficiency. Type and screen may be performed. Drug-dependent antibody testing is generally not needed for managing acute immune-mediated hemolysis but may be helpful for guiding future drug avoidance. (See <a class="local">'Additional tests for selected individuals'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stop the drug</strong> – The main treatment for drug-induced hemolysis is drug discontinuation; in most cases, the hemoglobin level increased over days to weeks. The drug should be avoided indefinitely. In some cases, drugs of a similar class are also avoided. The plan for future drug avoidance should be clearly indicated in the medical record. (See <a class="local">'Drug discontinuation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusions</strong> – Blood transfusions are given for severe anemia (eg, hemoglobin &lt;7 g/dL), or anemia that is expected to become severe without transfusion. Transfusions should <strong>not</strong> be withheld while obtaining or awaiting the results of laboratory testing or in complex crossmatching situations due to drug-induced red blood cell antibodies. The transfusion medicine service or blood bank can help weigh the risks and benefits of transfusion and provide emergency release blood if needed. (See <a class="local">'Indications for transfusions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other interventions</strong> – Additional therapies may be required for selected individuals:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Glucocorticoids and/or intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) for immune hemolysis. (See <a class="local">'Therapies for AIHA'</a> above.)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">Methylene blue</a>, ascorbic acid, or hemoperfusion for methemoglobinemia. (See <a class="local">'Therapy for methemoglobinemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-drug causes of hemolysis</strong> – General approaches to evaluating hemolysis are presented separately. (See  <a class="medical medical_review" href="/z/d/html/5932.html" rel="external">"Overview of hemolytic anemias in children"</a> and  <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults"</a>.)</p><p></p><p class="headingAnchor" id="H3604512680"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Hematology.</p><p>The UpToDate editorial staff also acknowledges the extensive contributions of William C Mentzer, MD, to earlier versions of this and many other topic reviews.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Brodsky RA. Warm Autoimmune Hemolytic Anemia. N Engl J Med 2019; 381:647.</a></li><li><a class="nounderline abstract_t">Tanios GE, Doley PB, Munker R. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Eur J Haematol 2019; 102:157.</a></li><li><a class="nounderline abstract_t">Fattizzo B, Rampi N, Barcellini W. Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors. Pharmaceuticals (Basel) 2022; 15.</a></li><li><a class="nounderline abstract_t">Mayer B, Bartolmäs T, Yürek S, Salama A. Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre. Transfus Med Hemother 2015; 42:333.</a></li><li><a class="nounderline abstract_t">Garbe E, Andersohn F, Bronder E, et al. Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study. Br J Haematol 2011; 154:644.</a></li><li><a class="nounderline abstract_t">Johnson ST, Fueger JT, Gottschall JL. One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia--a new paradigm. Transfusion 2007; 47:697.</a></li><li><a class="nounderline abstract_t">Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev 2010; 24:143.</a></li><li><a class="nounderline abstract_t">Hill QA, Stamps R, Massey E, et al. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol 2017; 177:208.</a></li><li><a class="nounderline abstract_t">Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 1996; 124:792.</a></li><li><a class="nounderline abstract_t">Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blood 2008; 111:16.</a></li><li><a class="nounderline abstract_t">Ward KE, McCarthy MW. Dapsone-induced methemoglobinemia. Ann Pharmacother 1998; 32:549.</a></li><li><a class="nounderline abstract_t">Coleman MD. Dapsone toxicity: some current perspectives. Gen Pharmacol 1995; 26:1461.</a></li><li><a class="nounderline abstract_t">Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990; 323:776.</a></li><li><a class="nounderline abstract_t">Jahoor F, Jackson A, Gazzard B, et al. Erythrocyte glutathione deficiency in symptom-free HIV infection is associated with decreased synthesis rate. Am J Physiol 1999; 276:E205.</a></li><li><a class="nounderline abstract_t">SPRIGGS AI, SMITH RS, GRIFFITH H, TRUELOVE SC. Heinz-body anaemia due to salicylazosulphapyridine. Lancet 1958; 1:1039.</a></li><li><a class="nounderline abstract_t">Nathan DM, Siegel AJ, Bunn HF. Acute methemoglobinemia and hemolytic anemia with phenazopyridine: possible relation to acute renal failure. Arch Intern Med 1977; 137:1636.</a></li><li><a class="nounderline abstract_t">Fincher ME, Campbell HT. Methemoglobinemia and hemolytic anemia after phenazopyridine hydrochloride (Pyridium) administration in end-stage renal disease. South Med J 1989; 82:372.</a></li><li><a class="nounderline abstract_t">Siddiqui MA. Chronic severe hemolytic anemia from phenazopyridine. Ann Intern Med 1995; 122:156; author reply 157.</a></li><li><a class="nounderline abstract_t">Rodriguez LF, Smolik LM, Zbehlik AJ. Benzocaine-induced methemoglobinemia: report of a severe reaction and review of the literature. Ann Pharmacother 1994; 28:643.</a></li><li><a class="nounderline abstract_t">Ferraro-Borgida MJ, Mulhern SA, DeMeo MO, Bayer MJ. Methemoglobinemia from perineal application of an anesthetic cream. Ann Emerg Med 1996; 27:785.</a></li><li><a class="nounderline abstract_t">Collins JF. Methemoglobinemia as a complication of 20% benzocaine spray for endoscopy. Gastroenterology 1990; 98:211.</a></li><li><a class="nounderline abstract_t">Marcovitz PA, Williamson BD, Armstrong WF. Toxic methemoglobinemia caused by topical anesthetic given before transesophageal echocardiography. J Am Soc Echocardiogr 1991; 4:615.</a></li><li><a class="nounderline abstract_t">Karim A, Ahmed S, Siddiqui R, Mattana J. Methemoglobinemia complicating topical lidocaine used during endoscopic procedures. Am J Med 2001; 111:150.</a></li><li><a class="nounderline abstract_t">Guertler AT, Pearce WA. A prospective evaluation of benzocaine-associated methemoglobinemia in human beings. Ann Emerg Med 1994; 24:626.</a></li><li><a class="nounderline abstract_t">Rehman HU. Methemoglobinemia. West J Med 2001; 175:193.</a></li><li><a class="nounderline abstract_t">Wason S, Detsky AS, Platt OS, Lovejoy FH Jr. Isobutyl nitrite toxicity by ingestion. Ann Intern Med 1980; 92:637.</a></li><li><a class="nounderline abstract_t">Bogart L, Bonsignore J, Carvalho A. Massive hemolysis following inhalation of volatile nitrites. Am J Hematol 1986; 22:327.</a></li><li><a class="nounderline abstract_t">Romeril KR, Concannon AJ. Heinz body haemolytic anaemia after sniffing volatile nitrites. Med J Aust 1981; 1:302.</a></li><li><a class="nounderline abstract_t">Beaupre SR, Schiffman FJ. Rush hemolysis. A 'bite-cell' hemolytic anemia associated with volatile liquid nitrite use. Arch Fam Med 1994; 3:545.</a></li><li><a class="nounderline abstract_t">Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol 2005; 42:137.</a></li><li><a class="nounderline abstract_t">Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet 1983; 2:193.</a></li><li><a class="nounderline abstract_t">Nakamura S, Yoshida T, Ohtake S, Matsuda T. Hemolysis due to high-dose intravenous gammaglobulin treatment for patients with idiopathic thrombocytopenic purpura. Acta Haematol 1986; 76:115.</a></li><li><a class="nounderline abstract_t">Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ. Hemolysis following intravenous immune globulin therapy. Transfusion 1986; 26:410.</a></li><li><a class="nounderline abstract_t">Brox AG, Cournoyer D, Sternbach M, Spurll G. Hemolytic anemia following intravenous gamma globulin administration. Am J Med 1987; 82:633.</a></li><li><a class="nounderline abstract_t">Comenzo RL, Malachowski ME, Meissner HC, et al. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr 1992; 120:926.</a></li><li><a class="nounderline abstract_t">Schrier SL. Pathophysiology of thalassemia. Curr Opin Hematol 2002; 9:123.</a></li><li><a class="nounderline abstract_t">Chiu D, Lubin B. Oxidative hemoglobin denaturation and RBC destruction: the effect of heme on red cell membranes. Semin Hematol 1989; 26:128.</a></li><li><a class="nounderline abstract_t">Hebbel RP, Eaton JW. Pathobiology of heme interaction with the erythrocyte membrane. Semin Hematol 1989; 26:136.</a></li><li><a class="nounderline abstract_t">Cortazzo JA, Lichtman AD. Methemoglobinemia: a review and recommendations for management. J Cardiothorac Vasc Anesth 2014; 28:1043.</a></li><li><a class="nounderline abstract_t">Iolascon A, Bianchi P, Andolfo I, et al. Recommendations for diagnosis and treatment of methemoglobinemia. Am J Hematol 2021; 96:1666.</a></li><li><a class="nounderline abstract_t">Umbreit J. Methemoglobin--it's not just blue: a concise review. Am J Hematol 2007; 82:134.</a></li><li><a class="nounderline abstract_t">Darling R, Roughton F. The effect of methemoglobin on the equilibrium between oxygen and hemoglobin. Am J Physiol 1942; 137:56.</a></li><li><a class="nounderline abstract_t">Chan TK, Chan WC, Weed RI. Erythrocyte hemighosts: a hallmark of severe oxidative injury in vivo. Br J Haematol 1982; 50:575.</a></li><li><a class="nounderline abstract_t">Yoo D, Lessin LS. Drug-associated "bite cell" hemolytic anemia. Am J Med 1992; 92:243.</a></li><li><a class="nounderline abstract_t">Coleman MD, Coleman NA. Drug-induced methaemoglobinaemia. Treatment issues. Drug Saf 1996; 14:394.</a></li><li><a class="nounderline abstract_t">Brandes JC, Bufill JA, Pisciotta AV. Amyl nitrite-induced hemolytic anemia. Am J Med 1989; 86:252.</a></li><li><a class="nounderline abstract_t">Rosen PJ, Johnson C, McGehee WG, Beutler E. Failure of methylene blue treatment in toxic methemoglobinemia. Association with glucose-6-phosphate dehydrogenase deficiency. Ann Intern Med 1971; 75:83.</a></li><li><a class="nounderline abstract_t">Citores MJ, Castejon R, Villarreal M, et al. CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia. Exp Hematol 2010; 38:165.</a></li><li><a class="nounderline abstract_t">Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998; 16:1885.</a></li><li><a class="nounderline abstract_t">Angus BJ, Chotivanich K, Udomsangpetch R, White NJ. In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood 1997; 90:2037.</a></li><li><a class="nounderline abstract_t">Newton PN, Chotivanich K, Chierakul W, et al. A comparison of the in vivo kinetics of Plasmodium falciparum ring-infected erythrocyte surface antigen-positive and -negative erythrocytes. Blood 2001; 98:450.</a></li><li><a class="nounderline abstract_t">Jauréguiberry S, Ndour PA, Roussel C, et al. Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. Blood 2014; 124:167.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Published reports of delayed hemolytic anemia after treatment with artesunate for severe malaria--worldwide, 2010-2012. MMWR Morb Mortal Wkly Rep 2013; 62:5.</a></li><li><a class="nounderline abstract_t">Rolling T, Agbenyega T, Issifou S, et al. Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria--a double-center prospective study. J Infect Dis 2014; 209:1921.</a></li><li><a class="nounderline abstract_t">Radin AI, Buckley P, Duffy TP. Interferon therapy for agnogenic myeloid metaplasia complicated by immune hemolytic anemia. Hematol Pathol 1991; 5:83.</a></li><li><a class="nounderline abstract_t">Stavroyianni N, Stamatopoulos K, Viniou N, et al. Autoimmune hemolytic anemia during alpha-interferon treatment in a patient with chronic myelogenous leukemia. Leuk Res 2001; 25:1097.</a></li><li><a class="nounderline abstract_t">Cauli C, Serra G, Chessa L, et al. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin. Haematologica 2006; 91:ECR26.</a></li><li><a class="nounderline abstract_t">Gentile I, Viola C, Reynaud L, et al. Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit. J Interferon Cytokine Res 2005; 25:283.</a></li><li><a class="nounderline abstract_t">Kazuta Y, Watanabe N, Sagawa K, et al. A case of autoimmune hemolytic anemia induced by IFN-beta therapy for type-C chronic hepatitis. Fukushima J Med Sci 1995; 41:43.</a></li><li><a class="nounderline abstract_t">Sacchi S, Kantarjian H, O'Brien S, et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13:2401.</a></li><li><a class="nounderline abstract_t">Takase K, Nakano T, Hamada M, et al. Hemolytic anemia provoked by recombinant alpha-interferon. J Gastroenterol 1995; 30:795.</a></li><li><a class="nounderline abstract_t">Arndt PA, Leger RM, Garratty G. Serologic characteristics of ceftriaxone antibodies in 25 patients with drug-induced immune hemolytic anemia. Transfusion 2012; 52:602.</a></li><li><a class="nounderline abstract_t">Marchand A, Galen RS, Van Lente F. The predictive value of serum haptoglobin in hemolytic disease. JAMA 1980; 243:1909.</a></li><li><a class="nounderline abstract_t">Petz LD, Fudenberg HH. Coombs-positive hemolytic anemia caused by penicillin administration. N Engl J Med 1966; 274:171.</a></li><li><a class="nounderline abstract_t">Danielson C, Houseworth J, Skipworth E, et al. Arsine toxicity treated with red blood cell and plasma exchanges. Transfusion 2006; 46:1576.</a></li><li><a class="nounderline abstract_t">Ng LL, NaiK RB, Polak A. Paraquat ingestion with methaemoglobinaemia treated with methylene blue. Br Med J (Clin Res Ed) 1982; 284:1445.</a></li><li><a class="nounderline abstract_t">Casey PB, Buckley BM, Vale JA. Methemoglobinemia following ingestion of a monolinuron/paraquat herbicide (Gramonol). J Toxicol Clin Toxicol 1994; 32:185.</a></li><li><a class="nounderline abstract_t">Reeves DJ, Saum LM, Birhiray R. I.V. ascorbic acid for treatment of apparent rasburicase-induced methemoglobinemia in a patient with acute kidney injury and assumed glucose-6-phosphate dehydrogenase deficiency. Am J Health Syst Pharm 2016; 73:e238.</a></li><li><a class="nounderline abstract_t">Rehman A, Shehadeh M, Khirfan D, Jones A. Severe acute haemolytic anaemia associated with severe methaemoglobinaemia in a G6PD-deficient man. BMJ Case Rep 2018; 2018.</a></li><li><a class="nounderline abstract_t">Goldstein GM, Doull J. Treatment of nitrite-induced methemoglobinemia with hyperbaric oxygen. Proc Soc Exp Biol Med 1971; 138:137.</a></li></ol></div><div id="topicVersionRevision">Topic 7104 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31412178" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Warm Autoimmune Hemolytic Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30347480" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35631383" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26696803" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Variability of Findings in Drug-Induced Immune Haemolytic Anaemia: Experience over 20 Years in a Single Centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21749359" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17381629" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia--a new paradigm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20650555" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Immune hemolytic anemia associated with drug therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28369704" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8610948" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18156501" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Glucose-6-phosphate dehydrogenase deficiency: a historical perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9606476" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Dapsone-induced methemoglobinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8690232" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Dapsone toxicity: some current perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2392131" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9886968" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Erythrocyte glutathione deficiency in symptom-free HIV infection is associated with decreased synthesis rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13540245" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Heinz-body anaemia due to salicylazosulphapyridine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/921457" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Acute methemoglobinemia and hemolytic anemia with phenazopyridine: possible relation to acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2922627" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Methemoglobinemia and hemolytic anemia after phenazopyridine hydrochloride (Pyridium) administration in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7992997" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Chronic severe hemolytic anemia from phenazopyridine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8069004" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Benzocaine-induced methemoglobinemia: report of a severe reaction and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8644973" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Methemoglobinemia from perineal application of an anesthetic cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2293580" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Methemoglobinemia as a complication of 20% benzocaine spray for endoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1760183" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Toxic methemoglobinemia caused by topical anesthetic given before transesophageal echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11498069" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Methemoglobinemia complicating topical lidocaine used during endoscopic procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8092589" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A prospective evaluation of benzocaine-associated methemoglobinemia in human beings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11527852" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Methemoglobinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7387007" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Isobutyl nitrite toxicity by ingestion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3717148" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Massive hemolysis following inhalation of volatile nitrites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6113538" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Heinz body haemolytic anaemia after sniffing volatile nitrites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8081534" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Rush hemolysis. A 'bite-cell' hemolytic anemia associated with volatile liquid nitrite use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16041663" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The changing spectrum of drug-induced immune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6135031" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effect of intravenous immunoglobulin in immune thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2433882" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hemolysis due to high-dose intravenous gammaglobulin treatment for patients with idiopathic thrombocytopenic purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3765031" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Hemolysis following intravenous immune globulin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3826125" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hemolytic anemia following intravenous gamma globulin administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1593353" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11844995" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pathophysiology of thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2658088" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Oxidative hemoglobin denaturation and RBC destruction: the effect of heme on red cell membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2658089" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Pathobiology of heme interaction with the erythrocyte membrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23953868" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Methemoglobinemia: a review and recommendations for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34467556" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Recommendations for diagnosis and treatment of methemoglobinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16986127" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Methemoglobin--it's not just blue: a concise review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The effect of methemoglobin on the equilibrium between oxygen and hemoglobin</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7066207" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Erythrocyte hemighosts: a hallmark of severe oxidative injury in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1546722" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Drug-associated "bite cell" hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8828017" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Drug-induced methaemoglobinaemia. Treatment issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2563312" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Amyl nitrite-induced hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5091568" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Failure of methylene blue treatment in toxic methemoglobinemia. Association with glucose-6-phosphate dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20026377" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9586905" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9292540" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11435316" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A comparison of the in vivo kinetics of Plasmodium falciparum ring-infected erythrocyte surface antigen-positive and -negative erythrocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24859359" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23302816" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Published reports of delayed hemolytic anemia after treatment with artesunate for severe malaria--worldwide, 2010-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24376273" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria--a double-center prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1894585" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Interferon therapy for agnogenic myeloid metaplasia complicated by immune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11684283" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Autoimmune hemolytic anemia during alpha-interferon treatment in a patient with chronic myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16785129" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15871666" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8606041" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A case of autoimmune hemolytic anemia induced by IFN-beta therapy for type-C chronic hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7666100" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8963402" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Hemolytic anemia provoked by recombinant alpha-interferon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880048" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Serologic characteristics of ceftriaxone antibodies in 25 patients with drug-induced immune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7365971" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The predictive value of serum haptoglobin in hemolytic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4159252" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Coombs-positive hemolytic anemia caused by penicillin administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16965586" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Arsine toxicity treated with red blood cell and plasma exchanges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6805560" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Paraquat ingestion with methaemoglobinaemia treated with methylene blue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8024655" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Methemoglobinemia following ingestion of a monolinuron/paraquat herbicide (Gramonol)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27099330" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : I.V. ascorbic acid for treatment of apparent rasburicase-induced methemoglobinemia in a patient with acute kidney injury and assumed glucose-6-phosphate dehydrogenase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29592989" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Severe acute haemolytic anaemia associated with severe methaemoglobinaemia in a G6PD-deficient man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5125507" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Treatment of nitrite-induced methemoglobinemia with hyperbaric oxygen.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
